Pre-made Isatuximab benchmark antibody ( Whole mAb, anti-CD38 therapeutic antibody, Anti-ADPRC1/ADPRC 1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-279-1mg	1mg	3090
GMP-Bios-ab-279-10mg	10mg	Inquiry
GMP-Bios-ab-279-100mg	100mg	Inquiry
GMP-Bios-ab-279-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody
INN Name	Isatuximab
Target	CD38
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	4cmh:BC
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi
Conditions Approved	Multiple myeloma
Conditions Active	Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer
Conditions Discontinued	Non-small cell lung cancer;Prostrate cancer;T-cell lymphoma
Development Tech	na